ReviewExpert opinion on drug safety2019
An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency.
Abstract readReview
In one paragraph
Review in Expert opinion on drug safety, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity.Clinical pharmacology and therapeutics · 2021Pooled it
- Conflicts of interest in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: associations with recommendations.The Cochrane database of systematic reviews · 2020Pooled it
- Clinical and Ecological Impact of an Educational Program to Optimize Antibiotic Treatments in Nursing Homes (PROA-SENIOR): A Cluster, Randomized, Controlled Trial and Interrupted Time-Series Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- HLA-B*44 Alleles and HLA-DQA1*03:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to Fluoroquinolones.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- An alveolar macrophage-targeted ciprofloxacin polymeric prodrug improves survival in a murine model ofAntimicrobial agents and chemotherapy · 2026Article
- Fluoroquinolone-Associated Disability: A Rodent Model Reveals Transient Neuropsychiatric and Persistent Gastrointestinal Effects of Low-Dose Ciprofloxacin.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Chemical Proteomics Reveals Human Off-Targets of Fluoroquinolone Induced Mitochondrial Toxicity.Angewandte Chemie (International ed. in English) · 2025Article
- A Prospective Randomized Pilot Study on the Efficacy of a Dietary Supplementation Regimen of Vitamin E and Selenium for the Prevention of Fluoroquinolone-Induced Tendinopathy.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Analyses of Adverse Drug Reactions to Fluoroquinolones in Spontaneous Reports Before and After the Referral and in Clinical Routine Cases.Drugs in R&D · 2025Article
- Fluoroquinolone-Mediated Tendinopathy and Tendon Rupture.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Sex-specific risk signals and onset patterns of drug-induced peripheral neuralgia: a 20-year pharmacovigilance analysis based on FAERS real-world dat.Frontiers in pharmacology · 2025Article
- (Fluoro)quinolone prescriptions for upper respiratory tract infections in the German outpatient sector: a health insurance claims analysis.GMS infectious diseases · 2025Article
- A Review on Fluoroquinolones' Toxicity to Freshwater Organisms and a Risk Assessment.Journal of xenobiotics · 2024Review
- Article
- Safety of fluoroquinolones.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024Review
- Which fluoroquinolone is safer when combined with bedaquiline for tuberculosis treatment: evidence from FDA Adverse Event Reporting System database from 2013 to 2024.Frontiers in pharmacology · 2024Article
- Antibiotic-induced neuropsychiatric toxicity: epidemiology, mechanisms and management strategies - a narrative literature review.Drugs in context · 2024Review
- RNA as an off-target for FDA-approved drugs.Nature chemistry · 2023Article
- Thoracic Aorta: Anatomy and Pathology.Diagnostics (Basel, Switzerland) · 2023Review
- Nitrofurantoin failure in males with an uncomplicated urinary tract infection: a primary care observational cohort study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2023Observational
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Andrew C BennettDepartment of Clinical Pharmacy and Outcomes Sciences, The University of South Carolina College of Pharmacy , Columbia , SC , USA.
Charles L BennettDepartment of Clinical Pharmacy and Outcomes Sciences, The University of South Carolina College of Pharmacy , Columbia , SC , USA.ORCID https://orcid.org/0000-0002-8645-5705
Bartlett J WitherspoonDepartment of Medicine, The WJB Dorn Veterans Administration Medical Center , Columbia , SC , USA.
Kevin B KnopfDepartment of Clinical Pharmacy and Outcomes Sciences, The University of South Carolina College of Pharmacy , Columbia , SC , USA.
Funding
Research for Adverse Drug-Events And Reports (RADAR)R01CA102713 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WEST, DENNIS PAUL · 2003 to 2010
$3.2MSouthern Oncology Network on Adverse Reactions (SONAR) - Focus on Tyrosine KinaseR01CA165609 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI BENNETT, CHARLES L. · 2012 to 2016
$2.2MResearch on Adverse Drug Events and Reports: Novel Multiple Myeloma DrugsR01CA125077 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WEST, DENNIS PAUL · 2007 to 2009
$1.7MNCI NIH HHS R01 CA102713NCI NIH HHS R01 CA125077NCI NIH HHS R01 CA165609
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAnti-Bacterial AgentsAortic AneurysmAortic DissectionAortic RuptureCiprofloxacinDisability EvaluationEuropean UnionHumansLevofloxacinMoxifloxacinNeurotoxicity SyndromesUnited StatesUnited States Food and Drug AdministrationAnti-Bacterial AgentsCiprofloxacinLevofloxacinMoxifloxacinadverse eventsFluoroquinolonesneuropsychiatric toxicityREMS (Risk Evaluation and Mitigation Strategy)restricted distribution
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.